use of tumor markers in testicular, prostate, colorectal, breast, and ...

64 Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
100. Catalona WJ, Vaitukaitis JL, Fair WR. Falsely positive specific
human chorionic gonadotropin assays in patients with testicular
tumors: conversion to negative with testosterone administration.
J Urol 1979;122:126–128.
101. Stenman UH, Alfthan H, Hotakainen K. Human chorionic
gonadotropin in cancer. Clin Biochem 2004;37:549–561.
102. Cole LA, Rinne KM, Shahabi S, Omrani A. False-positive hCG
assay results leading to unnecessary surgery and chemotherapy
and needless occurrences of diabetes and coma. Clin Chem
1999;45:313–314.
103. Saller B, Clara R, Spottl G, Siddle K, Mann K. Testicular cancer
secretes intact human choriogonadotropin (hCG) and its free
beta-subunit: evidence that hCG (hCG-beta) assays are the
most reliable in diagnosis and follow-up. Clin Chem 1990;
36:234–239.
104. Summers J, Raggatt P, Pratt J, Williams MV. Experience of discordant
beta hCG results by different assays in the management
of non-seminomatous germ cell tumours of the testis. Clin Oncol
(R Coll Radiol) 1999;11:388–392.
105. Li SS, Luedemann M, Sharief FS, Takano T, Deaven LL.
Mapping of human lactate dehydrogenase-A, -B, and -C genes
and their related sequences: the gene for LDHC is located with
that for LDHA on chromosome 11. Cytogenet Cell Genet
1988;48:16–18.
106. Looijenga LH, Zafarana G, Grygalewicz B, Summersgill B,
biec-Rychter M, Veltman J, et al. Role of gain of 12p in germ
cell tumour development. APMIS 2003;111:161–171.
107. Rosenberg C, van Gurp RJ, Geelen E, Oosterhuis JW, Looijenga
LH. Overrepresentation of the short arm of chromosome 12 is
related to invasive growth of human testicular seminomas and
nonseminomas. Oncogene 2000;19:5858–5862.
108. Summersgill B, Osin P, Lu YJ, Huddart R, Shipley J.
Chromosomal imbalances associated with carcinoma in situ and
associated testicular germ cell tumours of adolescents and
adults. Br J Cancer 2001;85:213–220.
109. von Eyben FE. A systematic review of lactate dehydrogenase
isoenzyme 1 and germ cell tumors. Clin Biochem 2001;
34:441–454.
110. Fishman WH. Perspectives on alkaline phosphatase isoenzymes.
Am J Med 1974;56:617–650.
111. Roelofs H, Manes T, Janszen T, Millan JL, Oosterhuis JW,
Looijenga LH. Heterogeneity in alkaline phosphatase isozyme
expression in human testicular germ cell tumours: An enzyme-/
immunohistochemical and molecular analysis. J Pathol 1999;
189:236–244.
112. Lange PH, Millan JL, Stigbrand T, Vessella RL, Ruoslahti E,
Fishman WH. Placental alkaline phosphatase as a tumor marker
for seminoma. Cancer Res 1982;42:3244–3247.
113. De Broe ME, Pollet DE. Multicenter evaluation of human placental
alkaline phosphatase as a possible tumor-associated antigen
in serum. Clin Chem 1988;34:1995–1999.
114. Mosselman S, Looijenga LH, Gillis AJ, van Rooijen MA, Kraft
HJ, van Zoelen EJ, Oosterhuis JW. Aberrant platelet-derived
growth factor alpha-receptor transcript as a diagnostic marker
for early human germ cell tumors of the adult testis. Proc Natl
Acad Sci U S A 1996;93:2884–2888.
115. de Bruijn HW, Sleijfer DT, Schraffordt Koops H, Suurmeijer AJ,
Marrink J, Ockhuizen T. Significance of human chorionic
gonadotropin, alpha-fetoprotein, and pregnancy-specific beta-1glycoprotein
in the detection of tumor relapse and partial remission
in 126 patients with nonseminomatous testicular germ cell
tumors. Cancer 1985;55:829–835.
116. Kuzmits R, Schernthaner G, Krisch K. Serum neuron-specific
enolase. A marker for responses to therapy in seminoma. Cancer
1987;60:1017–1021.
117. Fossa SD, Klepp O, Paus E. Neuron-specific enolase—a serum
tumour marker in seminoma? Br J Cancer 1992;65:297–299.
118. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer
statistics, 2007. CA Cancer J Clin 2007;57:43–66.
119. Sakr WA, Grignon DJ. Prostate cancer: indicators of aggressiveness.
Eur Urol 1997;32 Suppl 3:15–23.
120. Hayes DF, Bast RC, Desch CE, Fritsche H, Jr., Kemeny NE,
Jessup JM, et al. Tumor marker utility grading system: a framework
to evaluate clinical utility of tumor markers. J Natl Cancer
Inst 1996;88:1456–1466.
121. Excellence NIfHaC. Prostate cancer: Diagnosis and treatment.
http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11
924 (Accessed 24th May 2008 2008).
122. Makinen T, Tammela TL, Hakama M, Stenman UH, Rannikko
S, Aro J, et al. Tumor characteristics in a population-based
prostate cancer screening trial with prostate-specific antigen.
Clin Cancer Res 2003;9:2435–2439.
123. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA,
Schroder FH, de Koning HJ. Lead times and overdetection due
to prostate-specific antigen screening: estimates from the
European Randomized Study of Screening for Prostate Cancer.
J Natl Cancer Inst 2003;95:868–878.
124. Punglia RS, D’Amico AV, Catalona WJ, Roehl KA, Kuntz KM.
Effect of verification bias on screening for prostate cancer by
measurement of prostate-specific antigen. N Engl J Med
2003;349:335–342.
125. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M,
Downs J. The prostate specific antigen era in the United States
is over for prostate cancer: what happened in the last 20 years?
J Urol 2004;172:1297–1301.
126. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L,
Leinonen J. Serum concentrations of prostate specific antigen
and its complex with alpha 1-antichymotrypsin before diagnosis
of prostate cancer. Lancet 1994;344:1594–1598.
127. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation
of plasma prostate-specific antigen for detection of prostatic
cancer. Jama 1995;273:289–294.
128. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS,
Parnes HL, et al. Prevalence of prostate cancer among men with
a prostate-specific antigen level or =4.0 ng per milliliter. N
Engl J Med 2004;350:2239–2246.
129. Whittemore AS, Cirillo PM, Feldman D, Cohn BA. Prostate specific
antigen levels in young adulthood predict prostate cancer
risk: results from a cohort of Black and White Americans. J Urol
2005;174:872–876; discussion 876.
130. Lilja H, Ulmert D, Bjork T, Becker C, Serio AM, Nilsson JA,
et al. Long-term prediction of prostate cancer up to 25 years
before diagnosis of prostate cancer using prostate kallikreins
measured at age 44 to 50 years. J Clin Oncol 2007;25:431–436.
131. Wirth MP, Frohmuller HG. Prostate-specific antigen and
prostate acid phosphatase in the detection of early prostate cancer
and the prediction of regional lymph node metastases. Eur
Urol 1992;22:27–32.
132. Kontturi M. Is acid phosphatase (PAP) still justified in the management
of prostatic cancer? Acta Oncol 1991;30:169–170.
133. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a
randomized, population-based study of biennial screening using
serum prostate-specific antigen measurement to detect prostate
carcinoma. Cancer 2004;100:1397–1405.